Successor-in-Interest (Type 6 Parent Clinical Trial Optional)

Due: Jul 17, 2027

Description

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization status, often referred to in this announcement as Successor-In-Interest, may be submitted to this NOFO. Applications for change of recipient organization status are considered prior approval requests (as described in Section 8.1.2.8 of the NIH Grants Policy Statement) and will be routed for consideration...

Eligible Applicants- State governments- County governments- City or township governments- Special district governments- Independent school districts- Public and State controlled institutions of higher education- Native American tribal governments (Federally recognized)- Public housing authorities/Indian housing authorities- Native American tribal organizations (other than Federally recognized tribal governments)- Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education- Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education- Private institutions of higher education- For-profit organizations other than small businesses- Small businesses- Others

Additional Eligibility Information

Other Eligible Applicants include the following:Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Cont...

Funding TypeGrantCategories of Funding Activity- Education- HealthOpportunity TypeDiscretionary

Grantor Contact InformationSee Section VII. Agency Contacts within the full opportunity announcement for all other inquires.Grantor Emailgrantsinfo@nih.govOther Grantor InformationNIH Grants Information grantsinfo@nih.gov

Additional Informationhttps://grants.nih.gov/grants/guide/pa-files/PA-24-253.htmlSupporting Linkhttp://grants.nih.gov/grants/guide/pa-files/PA-24-253.html

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

Similar Grants

Eligibility

Profile

Finance

Other

Similar Grants

Successor-in-Interest (Type 6 Parent Clinical Trial Optional)

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)

Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement Clinical Trial Optional)

Successor-in-Interest (Type 6 Parent Clinical Trial Optional)

Start finding grants with Atom for

$0 today

$30 Billed monthly after 7-day trial. Cancel anytime.

Personalized grant emails delivered weekly, right to your inbox.

AI powered search engine with both keyword and semantic search capabilities.

Grant filters to find the perfect funding opportunities.

Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)

Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement Clinical Trial Optional)